Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 18 Smoldering Multiple Myeloma 2 Hematologic Neoplasms 2 Recurrence 1 Lymphoma 1 Leukemia, Plasma Cell 1

Interventions

Rituximab 173 Cyclophosphamide 156 Vincristine 72 fludarabine phosphate 71 Etoposide 68 Doxorubicin 68 Prednisone 66 Filgrastim 58 Methotrexate 52 Cytarabine 51 fludarabine 49 Melphalan 48 Busulfan 47 Tacrolimus 41 Whole-Body Irradiation 39 Mycophenolic Acid 39 Granulocyte Colony-Stimulating Factor 37 Antilymphocyte Serum 31 Peripheral Blood Stem Cell Transplantation 30 Radiotherapy 27 Lenalidomide 25 Dexamethasone 25 Carmustine 23 Stem Cell Transplantation 22 Cyclosporine 22 Bortezomib 22 Gemcitabine 20 Bendamustine Hydrochloride 20 ibritumomab tiuxetan 19 Alemtuzumab 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Lymphoma × elotuzumab × Clear all

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡